Free Trial

Laboratory Co. of America (LH) Stock Forecast & Price Target

Laboratory Co. of America logo
$228.61 +1.64 (+0.72%)
(As of 12/20/2024 05:31 PM ET)

Laboratory Co. of America - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
12

Based on 16 Wall Street analysts who have issued ratings for Laboratory Co. of America in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 4 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for LH.

Consensus Price Target

$258.62
13.13% Upside
According to the 16 analysts' twelve-month price targets for Laboratory Co. of America, the average price target is $258.62. The highest price target for LH is $289.00, while the lowest price target for LH is $230.00. The average price target represents a forecasted upside of 13.13% from the current price of $228.61.
Get the Latest News and Ratings for LH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Laboratory Co. of America and its competitors.

Sign Up

LH Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
10 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$258.62$255.92$251.27$243.67
Forecasted Upside13.13% Upside6.45% Upside13.07% Upside8.77% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

LH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Laboratory Co. of America Stock vs. The Competition

TypeLaboratory Co. of AmericaMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside13.13% Upside25,828.56% Upside14.54% Upside
News Sentiment Rating
Positive News

See Recent LH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/17/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$260.00 ➝ $270.00+17.38%
12/13/2024Bank of America
3 of 5 stars
 Boost TargetBuy ➝ Buy$262.00 ➝ $271.00+16.67%
12/10/2024Jefferies Financial Group
2 of 5 stars
 Reiterated RatingBuy$265.00 ➝ $275.00+16.45%
10/30/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Herholdt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
10/30/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
10/28/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$235.00 ➝ $240.00+6.14%
10/25/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$234.00 ➝ $249.00+8.69%
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$282.00 ➝ $289.00+25.61%
9/24/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetIn-Line ➝ In-Line$250.00 ➝ $240.00+8.83%
8/2/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$260.00 ➝ $270.00+14.63%
8/2/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$220.00 ➝ $230.00-2.35%
8/2/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$255.00 ➝ $275.00+18.79%
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$261.00 ➝ $243.00+25.49%
3/25/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$250.00+17.23%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$260.00+18.63%
10/31/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$257.00 ➝ $230.00+16.07%
8/14/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$290.00 ➝ $270.00+23.85%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$247.41 ➝ $231.00+8.14%
4/26/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$260.00 ➝ $235.00+6.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:41 AM ET.


Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these Laboratory Co. of America pros and cons to contact@marketbeat.com.

Laboratory Co. of America
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

  • The company recently reported earnings per share (EPS) of $3.50, exceeding analysts' expectations of $3.48, indicating strong financial performance and effective management.
  • Laboratory Co. of America Holdings achieved a revenue of $3.28 billion for the last quarter, surpassing the anticipated $3.26 billion, showcasing its robust market position and demand for its services.
  • The current stock price is $237.35, which reflects a stable market capitalization of approximately $19.85 billion, suggesting a solid investment opportunity in a well-established company.
  • With a return on equity of 15.27%, the company demonstrates effective use of shareholders' equity to generate profits, which is a positive indicator for potential investors.
  • The firm has shown a year-over-year revenue growth of 7.4%, indicating a strong upward trend in its business operations and potential for future profitability.

Laboratory Co. of America
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

  • The stock has experienced a recent decline of 1.3%, which may indicate volatility and potential risks associated with investing in the company at this time.
  • Insider selling activity has been notable, with executives selling a total of 24,572 shares valued at over $5.9 million in the last three months, which could signal a lack of confidence in the company's short-term prospects.
  • The company has a high price-to-earnings (P/E) ratio of 45.91, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Laboratory Co. of America Holdings has a debt-to-equity ratio of 0.66, indicating a moderate level of debt that could pose risks if the company faces financial challenges.
  • Despite recent revenue growth, the net margin of 3.43% is relatively low, which may raise concerns about the company's profitability and efficiency in managing costs.

LH Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Laboratory Co. of America is $258.62, with a high forecast of $289.00 and a low forecast of $230.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LH shares.

According to analysts, Laboratory Co. of America's stock has a predicted upside of 13.13% based on their 12-month stock forecasts.

Over the previous 90 days, Laboratory Co. of America's stock had 2 upgrades by analysts.

Laboratory Co. of America has been rated by research analysts at Bank of America, Barclays, Evercore ISI, Hsbc Global Res, HSBC, Jefferies Financial Group, Morgan Stanley, Piper Sandler, and Robert W. Baird in the past 90 days.

Analysts like Laboratory Co. of America more than other "medical" companies. The consensus rating score for Laboratory Co. of America is 2.81 while the average consensus rating score for "medical" companies is 2.81. Learn more on how LH compares to other companies.


This page (NYSE:LH) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners